SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-24-117970
Filing Date
2024-04-26
Accepted
2024-04-26 16:05:31
Documents
11
Period of Report
2024-06-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A d730272ddef14a.htm DEF 14A 471012
2 GRAPHIC g730272dsp1a.jpg GRAPHIC 5422
3 GRAPHIC g730272dsp1b.jpg GRAPHIC 28811
4 GRAPHIC g730272dsp1c.jpg GRAPHIC 1776
5 GRAPHIC g730272dsp1d.jpg GRAPHIC 1514
6 GRAPHIC g730272dsp1e.jpg GRAPHIC 1426
7 GRAPHIC g730272dsp2.jpg GRAPHIC 3991
8 GRAPHIC g730272g01b98.jpg GRAPHIC 23694
9 GRAPHIC g730272g39g39.jpg GRAPHIC 121010
10 GRAPHIC g730272g60d25.jpg GRAPHIC 34707
11 GRAPHIC g730272g75l19.jpg GRAPHIC 9734
  Complete submission text file 0001193125-24-117970.txt   793340
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51531 | Film No.: 24883547
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)